PTCT - PTC THERAPEUTICS, INC.

QQQ $ 633.32 $ 0.00 (0 %)

DIA $ 475.83 $ -1.36 (-0.29 %)

SPY $ 684.65 $ 0.00 (0 %)

TLT $ 90.18 $ 0.00 (0 %)

GLD $ 370.32 $ 0.00 (0 %)

Previous Close

$ 68.11

Open

$ 67.36

Bid

$ 66.08 x 1

Ask

$ 74.47 x 4

Day's Range

-- - --

52 Week Range

$ 35.95 - $ 69.88

Volume

855,733

Average Volume

Market Cap

5.41B

Beta (5Y Monthly)

$ 1.10

PE Ratio (TTM)

$ 8.60

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-07-2025	06-30-2025	10-Q
2	05-06-2025	03-31-2025	10-Q
3	02-27-2025	12-31-2024	10-K
4	11-07-2024	09-30-2024	10-Q
5	08-08-2024	06-30-2024	10-Q
6	04-25-2024	03-31-2024	10-Q
7	02-29-2024	12-31-2023	10-K
8	10-26-2023	09-30-2023	10-Q
9	08-03-2023	06-30-2023	10-Q
10	04-27-2023	03-31-2023	10-Q
11	02-21-2023	12-31-2022	10-K
12	10-27-2022	09-30-2022	10-Q
13	08-04-2022	06-30-2022	10-Q
14	05-03-2022	03-31-2022	10-Q
15	02-22-2022	12-31-2021	10-K
16	10-28-2021	09-30-2021	10-Q
17	07-29-2021	06-30-2021	10-Q
18	05-04-2021	03-31-2021	10-Q
19	02-25-2021	12-31-2020	10-K
20	10-29-2020	09-30-2020	10-Q
21	08-05-2020	06-30-2020	10-Q
22	04-30-2020	03-31-2020	10-Q
23	03-02-2020	12-31-2019	10-K
24	10-30-2019	09-30-2019	10-Q
25	08-06-2019	06-30-2019	10-Q
26	05-02-2019	03-31-2019	10-Q
27	03-01-2019	12-31-2018	10-K
28	11-05-2018	09-30-2018	10-Q
29	08-07-2018	06-30-2018	10-Q
30	05-09-2018	03-31-2018	10-Q
31	03-06-2018	12-31-2017	10-K
32	11-02-2017	09-30-2017	10-Q
33	08-09-2017	06-30-2017	10-Q
34	05-08-2017	03-31-2017	10-Q
35	03-16-2017	12-31-2016	10-K
36	11-03-2016	09-30-2016	10-Q
37	08-04-2016	06-30-2016	10-Q
38	05-05-2016	03-31-2016	10-Q
39	02-29-2016	12-31-2015	10-K
40	11-09-2015	09-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Jefferies Maintains Buy on PTC Therapeutic...
10/28/2025 18:54:28

Jefferies analyst Kelly Shi maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and raises the price target from $63 to $77.

PTC Therapeutics Could Challenge BioMarin ...
09/08/2025 17:56:24

BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in...

Cantor Fitzgerald Reiterates Overweight on...
09/03/2025 13:49:29

Cantor Fitzgerald analyst Kristen Kluska reiterates PTC Therapeutics (NASDAQ:PTCT) with a Overweight and maintains $118 pric...

ptc-therapeutics-stock-is-stuck-in-a-multi-year-slump

PTC Therapeutics Stock Is Stuck In A Multi...
08/21/2025 14:00:45

PTC Therapeutics is stuck with uncertainty stretching through 2030. Here's why the stock remains a long-term avoid.

Wells Fargo Maintains Overweight on PTC Th...
08/20/2025 18:42:36

Wells Fargo analyst Tiago Fauth maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and lowers the price target from ...

Morgan Stanley Maintains Overweight on PTC...
08/20/2025 15:53:58

Morgan Stanley analyst Jeffrey Hung maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and lowers the price target f...

B of A Securities Maintains Buy on PTC The...
08/20/2025 12:21:22

B of A Securities analyst Tazeen Ahmad maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and lowers the price target from ...

ptc-therapeutics-faces-fda-rejection-on-rare-disease-treatment-over-efficacy-concerns

PTC Therapeutics Faces FDA Rejection On Ra...
08/19/2025 15:20:22

FDA rejected PTC Therapeutics' vatiquinone for Friedreich's ataxia, citing insufficient efficacy data and requiring ano...

Trading Halt: Halt status updated at 8:25:...
08/19/2025 12:25:16

PTC Therapeutics Receives Complete Respons...
08/19/2025 12:03:56

Trading Halt: Halted at 7:55:00 a.m. ET - ...
08/19/2025 11:55:04

RBC Capital Maintains Outperform on PTC Th...
08/08/2025 18:29:10

RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Outperform and raises the price target fr...

Wells Fargo Maintains Overweight on PTC Th...
08/08/2025 15:26:13

Wells Fargo analyst Tiago Fauth maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from ...

PTC Therapeutics Affirms FY2025 Sales Guid...
08/07/2025 20:02:35

PTC Therapeutics (NASDAQ:PTCT) affirms FY2025 sales outlook from $650.00 million-$800.00 million to $650.00 million-$800.00 mil...

PTC Therapeutics Q2 EPS $(0.83) Beats $(0....
08/07/2025 20:02:05

PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(0.83) per share which beat the analyst consensus estimate of $(0....

Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

PTC Therapeutics Earnings Preview
08/06/2025 17:02:22

sephience-gets-fda-approval-now-a-key-revenue-driver-for-ptc-therapeutics

Sephience Gets FDA Approval, Now A Key Rev...
07/29/2025 17:58:58

PTC Therapeutics secures FDA approval for Sephience in PKU, launching August with analysts projecting strong revenue and broad ...

Truist Securities Maintains Buy on PTC The...
07/29/2025 15:54:13

Truist Securities analyst Joon Lee maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and raises the price target from $80 ...

these-analysts-increase-their-forecasts-on-ptc-therapeutics

These Analysts Increase Their Forecasts On...
07/29/2025 15:23:21